CeQur has appointed Douglas Lawrence as CEO, effective immediately. Lawrence replaces CeQur founder James Peterson, who is retiring from the role, but will continue to serve as Vice Chairman of CeQur's Board of Directors.
As CEO, Lawrence will lead the transition of CeQur from pilot manufacturing stage through to establishment of high-volume manufacturing capacity, regulatory approval in the US and PaQ international commercialisation.
CeQur's PaQ insulin delivery device enables patients to experience continuous insulin infusion without the burden of daily injections. PaQ provides three days of consistent, basal insulin along with on-demand bolus insulin. PaQ can reduce known barriers to insulin therapy and has proven effective in clinical trials and usability studies. The device has CE mark approval.